Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy

Basit Öğe Kaydı
dc.authorid0000-0002-5299-9480en_US
dc.authorid0000-0002-8390-5109en_US
dc.authorid0000-0003-4618-1110en_US
dc.contributor.authorGürkan, Fuat
dc.contributor.authorHaspolat, Yusuf Kenan
dc.contributor.authorBoşnak, Mehmet
dc.contributor.authorDikici, Bünyamin
dc.contributor.authorDerman, Orhan
dc.contributor.authorEce, Aydın
dc.date.accessioned2021-12-09T12:19:10Z
dc.date.available2021-12-09T12:19:10Z
dc.date.issued1999en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractManagement of severe acute asthma attacks in children sometimes bring difficulties to the physician. Some current treatment strategies have focused on intravenous magnesium sulphate administration in patients nonresponding to therapy with beta-2 agonists and corticosteroids. The use and efficacy of this drug has been discussed in this randomized, double-blind, placebo-controlled clinical trial consisting of 20 children with moderate to severe acute asthma exacerbation admitted to the emergency department in Dicle University Hospital, Turkey. Magnesium sulphate infusion therapy of 40 mg/kg doses (maximum 2 g) or an equivalent volume of normal saline solution were administered to randomly assigned 10 patients in each group to the selected patients who were being treated for an acute asthma exacerbation with a peak expiratory flow rate (PEFR) less than 60% of the predicted value after receiving three beta-2 adrenergic nebulizer treatments (salbutamol) given at an interval of 20 minutes each. Vital signs, PEFR and physical examinations were serially recorded at 15 minutes intervals for a total of 90 minutes after the initiation of magnesium sulphate therapy. At 30 minutes, compared with the placebo group, the magnesium sulphate receiving group had lower clinical asthma scores (4.0+/-0.5 vs. 5.5+/-0.5, p = 0.0002) and a significantly greater percentage of improvement from baseline in PEFR (43.0+/-6.3% vs. 14.6+/-3.7%, p = 0.0002). These significant changes persisted at 45, 60, 75 and 90 minutes. No significant side effects were observed. In conclusion, severe asthmatic cases may benefit from magnesium sulphate therapy when beta-2 agonists are inadequate in preventing deterioration.en_US
dc.identifier.citationGürkan, F., Haspolat, Y. K., Boşnak, M., Dikici, B., Derman, O., Ece, A. ve diğerleri. (1999). Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy. European Journal of Emergency Medicine, 6(3), 201-205.en_US
dc.identifier.doi10.1097/00063110-199909000-00005
dc.identifier.endpage205en_US
dc.identifier.issn0969-9546
dc.identifier.issn1473-5695
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-0033182968
dc.identifier.scopusqualityQ2
dc.identifier.startpage201en_US
dc.identifier.urihttps://hdl.handle.net/11468/8389
dc.identifier.volume6en_US
dc.indekslendigikaynakScopus
dc.institutionauthorGürkan, Fuat
dc.institutionauthorHaspolat, Yusuf Kenan
dc.institutionauthorBoşnak, Mehmet
dc.institutionauthorDikici, Bünyamin
dc.institutionauthorDerman, Orhan
dc.institutionauthorEce, Aydın
dc.language.isoenen_US
dc.publisherWolters Kluweren_US
dc.relation.ispartofEuropean Journal of Emergency Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute asthmaen_US
dc.subjectMagnesium sulphateen_US
dc.subjectIntravenous therapyen_US
dc.subjectChildrenen_US
dc.titleIntravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapyen_US
dc.titleIntravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
intravenous magnesium sulphate in the management acute asthma.pdf
Boyut:
5.49 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu